Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001523
Abstract: Although uncommon epidermal growth factor receptor (EGFR) mutations account for 10-15% EGFR mutant non-small cell lung cancer (NSCLC) patients, clinical evidence for uncommon EGFR mutations, such as complex mutations remain limited. In this study, we… read more here.
Keywords: first line; lung; osimertinib monotherapy; l833v h835l ... See more keywords
Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096241300929
Abstract: Lung cancer, a leading cause of cancer mortality, often involves epidermal growth factor receptor (EGFR) mutations, common in 17% of Caucasian and 40% of Asian non-small-cell lung cancer (NSCLC) patients. While the exon 19 deletion… read more here.
Keywords: cancer; h835l mutations; lung cancer; l833v h835l ... See more keywords
Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2025.1658583
Abstract: Background Lung cancer remains the leading cause of cancer-related mortality worldwide. With advancements in molecularly targeted therapies, Epidermal growth factor receptor (EGFR) mutations have emerged as critical therapeutic targets in advanced lung adenocarcinoma. However, the… read more here.
Keywords: egfr; egfr l833v; advanced lung; lung ... See more keywords